Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.578, 2009-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Zoledronic acid reduces skeletal complications in prostate cancer
Inpharma, Vol. 1, Iss. 1364, 2002-01 ,pp. :
Access to resources
Recommend
Sunitinib cost effective for renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 532, 2007-01 ,pp. :
Zoledronic acid cost effective in preventing AI-associated bone loss
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 564, 2008-01 ,pp. :
High renal impairment rate with zoledronic acid in cancer patients
Inpharma, Vol. 1, Iss. 1517, 2005-01 ,pp. :
Sorafenib a cost-effective option in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 516, 2006-01 ,pp. :